Central high-grade osteosarcoma of bone: Diagnostic and genetic considerations

Current Diagnostic Pathology

Volumn 11, Issue 6, 2005, Pages 390-399

  Cleton Jansen, Anne Marie ^a   Buerger, Horst ^b   Hogendoorn, Pancras C W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Genetic aberrations; Hereditary osteosarcoma; Histology; Imaging; Osteogenic tumour

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 2; CISPLATIN; CYCLIN DEPENDENT KINASE 4; CYTOSTATIC AGENT; DOXORUBICIN; IMATINIB; METHOTREXATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; TELOMERASE; TETROFOSMIN TC 99M; TRASTUZUMAB;

BONE RADIOGRAPHY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONFERENCE PAPER; CYTOLOGY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG TARGETING; EXTRACELLULAR MATRIX; FAMILIAL CANCER; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GERM LINE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIMB SALVAGE; MOLECULAR GENETICS; OSTEOID; OSTEOSARCOMA; PAGET BONE DISEASE; PROGNOSIS; PROTEIN EXPRESSION; RETINOBLASTOMA; ROTHMUND THOMSON SYNDROME; TELOMERE;

EID: 27644509946     PISSN: 09686053     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cdip.2005.08.005     Document Type: Conference Paper

References (48)

1. C.D.M. Fletcher, K.K. Unni, and F. Mertens Osteogenic tumours C.D.M. Fletcher K.K. Unni F. Mertens Pathology and genetics of tumours of soft tissue and bone 2002 IARCPress Lyon 259 290
2. A.G. Huvos Malignant surface lesions of bone Curr Diagn Pathol 7 2001 247 250
3. P.C.W. Hogendoorn, J.V.M.G. Bovée, M. Karperien, and A.M. Cleton-Jansen Skeletogenesis: Genetics Nature encyclopedia of the human genome 2003 306 313
4. B. Fuchs, and D.J. Pritchard Etiology of osteosarcoma Clin Orthop Relat Res 397 2002 40 52
5. E.I. Hauben, S. Weeden, J. Pringle, E.A. Van Marck, and P.C. Hogendoorn Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup Eur J Cancer 38 2002 1218 1225
6. J. Baselga, L. Gianni, C. Geyer, E.A. Perez, A. Riva, and C. Jackisch Future options with trastuzumab for primary systemic and adjuvant therapy Semin Oncol 31 2004 51 57
7. J.K. Anninga, M.J. Van de Vijver, and A.M. Cleton-Jansen Overexpression of the Her-2 oncogene does not play a role in high-grade osteosarcomas Eur J Cancer 40 2004 963 970
8. N. Baldini, K. Scotlandi, and G. Barbanti-Brodano Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome N Engl J Med 333 1995 1380 1385
9. F.A. Hoffer Primary skeletal neoplasms: osteosarcoma and Ewing sarcoma Top Magn Reson Imaging 13 2002 231 239
10. H.J. Van der Woude, J.L. Bloem, and P.C.W. Hogendoorn Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities Skeletal Radiol 27 1998 57 71
11. S.J. O'Flanagan, J.P. Stack, H.M.J. McGee, P. Dervan, and B. Hurson Imaging of intramedullary tumour spread in osteosarcoma. A comparison of techniques J Bone Joint Surg [Br] 73B 1991 998 1001
12. Z. Burak, J.L. Moretti, and O. Ersoy 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression J Nucl Med 44 2003 1394 1401
13. A.G. Huvos Osteogenic sarcoma A.G. Huvos Bone tumors. Diagnosis, treatment, and prognosis 1991 W.B. Saunders Company Philadelphia 85 223
14. D. Fabbro, S. Ruetz, and E. Buchdunger Protein kinases as targets for anticancer agents: from inhibitors to useful drugs Pharmacol Ther 93 2002 79 98
15. E.C. McGary, K. Weber, and L. Mills Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571 Clin Cancer Res 8 2002 3584 3591
16. P.J. Houghton, G.S. Germain, and F.C. Harwood Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro Cancer Res 64 2004 2333 2337
17. C. Khanna, X. Wan, and S. Bose The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis Nat Med 10 2004 182 186
18. A.A. Sandberg, and J.A. Bridge Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors Cancer Genet Cytogenet 145 2003 1 30
19. T.K. Man, X.Y. Lu, and K. Jaeweon Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma BMC Cancer 4 2004 45
20. J. Atiye, M. Wolf, and S. Kaur Gene amplifications in osteosarcoma-CGH microarray analysis Genes Chromosomes Cancer 42 2005 158 163
21. C.C. Lau, C.P. Harris, and X.Y. Lu Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma Genes Chromosomes Cancer 39 2004 11 21
22. T. Ozaki, K.L. Schaefer, and D. Wai Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas Int J Cancer 102 2002 355 365
23. J.A. Squire, J. Pei, and P. Marrano High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays Genes Chromosomes Cancer 38 2003 215 225
24. C. Stock, L. Kager, F.M. Fink, H. Gadner, and P.F. Ambros Chromosomal regions involved in the pathogenesis of osteosarcomas Genes Chromosomes Cancer 28 2000 329 336
25. K.K. Wong, Y.T. Tsang, and J. Shen Allelic imbalance analysis by high-density single-nucleotide polymorphic allele (SNP) array with whole genome amplified DNA Nucl Acids Res 32 2004 e69
26. M. van Dartel, and T.J. Hulsebos Amplification and overexpression of genes in 17p11.2∼p12 in osteosarcoma Cancer Genet Cytogenet 153 2004 77 80
27. J. Henriksen, T.H. Aagesen, G.M. Maelandsmo, R.A. Lothe, O. Myklebost, and A. Forus Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation Oncogene 22 2003 5358 5361
28. G.P. Nielsen, K.L. Burns, A.E. Rosenberg, and D.N. Louis CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations Am J Pathol 153 1998 159 163
29. G. Wei, F. Lonardo, and T. Ueda CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons Int J Cancer 80 1999 199 204
30. J.S. Wunder, N. Gokgoz, and R. Parkes TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study J Clin Oncol 23 2005 1483 1490
31. M. Overholtzer, P.H. Rao, and R. Favis The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability Proc Natl Acad Sci USA 100 2003 11547 11552
32. C.W. Miller, T. Ikezoe, and U. Krug Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors Genes Chromosomes Cancer 33 2002 17 21
33. G.A. Ulaner, H.Y. Huang, and J. Otero Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma Cancer Res 63 2003 1759 1763
34. R.P. Sanders, R. Drissi, C.A. Billups, N.C. Daw, M.B. Valentine, and J.S. Dome Telomerase expression predicts unfavorable outcome in osteosarcoma J Clin Oncol 22 2004 3790 3797
35. A. Kido, R. Schneider-Stock, K. Hauptmann, and A. Roessner Telomerase activity in juxtacortical and conventional high-grade osteosarcomas: correlation with grade, proliferative activity and clinical response to chemotherapy Cancer Lett 196 2003 109 115
36. L.J. Van't Veer, H. Dai, and M.J. Van de Vijver Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
37. C. Khanna, J. Khan, and P. Nguyen Metastasis-associated differences in gene expression in a murine model of osteosarcoma Cancer Res 61 2001 3750 3759
38. P. Leonard, T. Sharp, and S. Henderson Gene expression array profile of human osteosarcoma Br J Cancer 89 2003 2284 2288
39. M. Wolf, W. El Rifai, and M. Tarkkanen Novel findings in gene expression detected in human osteosarcoma by cDNA microarray Cancer Genet Cytogenet 123 2000 128 132
40. T. Nakano, M. Tani, and Y. Ishibashi Biological properties and gene expression associated with metastatic potential of human osteosarcoma Clin Exp Metastasis 20 2003 665 674
41. E.I. Hauben, J. Arends, J.P. Vandenbroucke, C.J. van Asperen, E. Van Marck, and P.C. Hogendoorn Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma Eur J Hum Genet 11 2003 611 618
42. E. Matsunaga Hereditary retinoblastoma: host resistance and second primary tumors J Natl Cancer Inst 65 1980 47 51
43. L.L. Wang, A. Gannavarapu, and C.A. Kozinetz Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome J Natl Cancer Inst 95 2003 669 674
44. K. Nishijo, T. Nakayama, and T. Aoyama Mutation analysis of the RECQL4 gene in sporadic osteosarcomas Int J Cancer 111 2004 367 372
45. A.E. Hughes, S.H. Ralston, and J. Marken Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis Nat Genet 24 2000 45 48
46. M.J. Nellissery, S.S. Padalecki, and Z. Brkanac Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone Am J Hum Genet 63 1998 817 824
47. T.L. Johnson-Pais, M.J. Nellissery, and D.G. Ammerman Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma Int J Cancer 105 2003 285 288
48. A.B. Sparks, S.N. Peterson, and C. Bell Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma Calcif Tissue Int 68 2001 151 155